Canaccord Genuity Downgrades Protalix BioTherapeutics (PLX) to Hold
Tweet Send to a FriendGet Alerts PLX Hot Sheet
Price: $5.20 --0%
Rating Summary:
2 Buy, 9 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 13
Rating Summary:
2 Buy, 9 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 13
Trade PLX Now!
Canaccord Genuity downgraded Protalix BioTherapeutics (NYSE: PLX) from Buy to Hold, maintains price target of $8.00.
For an analyst ratings summary and ratings history on Protalix BioTherapeutics click here. For more ratings news on Protalix BioTherapeutics click here.
Shares of Protalix BioTherapeutics closed at $6.19 yesterday, with a 52 week range of $4.06-$7.33.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
For an analyst ratings summary and ratings history on Protalix BioTherapeutics click here. For more ratings news on Protalix BioTherapeutics click here.
Shares of Protalix BioTherapeutics closed at $6.19 yesterday, with a 52 week range of $4.06-$7.33.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: MKM Partners Downgrades Alkermes (ALKS) to Sell
- Goldman Sachs Downgrades Aixtron (AIXG) to Neutral
- Canaccord Genuity Downgrades Cirrus Logic (CRUS) to Hold
Create E-mail Alert Related Categories
Downgrades
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
